IP Verse

Method For Predicting Responsiveness To Cancer Treatment Using P300-Inhibiting Compound - EP3121274

The patent EP3121274 was granted to Daiichi Sankyo on Dec 18, 2019. The application was originally filed on Feb 23, 2015 under application number EP15752232A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3121274

DAIICHI SANKYO
Application Number
EP15752232A
Filing Date
Feb 23, 2015
Status
Granted And Under Opposition
Nov 15, 2019
Publication Date
Dec 18, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CELLCENTRICSep 16, 2020CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2008157680
INTERNATIONAL-SEARCH-REPORTWO2011085039
INTERNATIONAL-SEARCH-REPORTWO2015005473
OPPOSITIONWO2011085039
OPPOSITIONWO2013148114
OTHERWO2011085039
SEARCHWO2011085039

Non-Patent Literature (NPL) Citations (39) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Charles G. Mullighan ET AL, "CREBBP mutations in relapsed acute lymphoblastic leukaemia /NIH Public Access Author Manuscript/", Nature / PMC, (20110910), pages 1 - 13, XP055397612
EXAMINATION- Laura Pasqualucci ET AL, "Inactivating mutations of acetyltransferase genes in B-cell lymphoma", Nature, GB, (20110310), vol. 471, no. 7337, doi:10.1038/nature09730, ISSN 0028-0836, pages 189 - 195, XP055361688
INTERNATIONAL-SEARCH-REPORT- KISHIMOTO M. et al., "Mutations and deletions of the CBP gene in human lung cancer.", Clin. Cancer Res., (20050000), vol. 11, pages 512 - 519, XP055221483 [X] 4 * (Figure, Materials and Methods) * [A] 1, 5-6
INTERNATIONAL-SEARCH-REPORT- TAKASHI KONO, "Gan no Kobetsuka Chiryo to Soyaku", Japanese Journal of Clinical Medicine, (20140220), vol. 72, no. suppl.2, pages 34 - 39 [A] 1, 4-6 * (figures) *
INTERNATIONAL-SEARCH-REPORT- CHAN D.A. et al., "Harnessing synthetic lethal interactions in anticancer drug discovery.", Nat. Rev. Drug. Discov., (20110000), vol. 10, no. 5, ISSN 1474-1776, pages 351 - 364, XP055204267 [A] 1, 4-6 * (Abstract) *
INTERNATIONAL-SEARCH-REPORT- OGIWARA H. et al., "Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors.", Oncogene, (20110000), vol. 30, no. 18, ISSN 0950-9232, pages 2135 - 2146, XP055221484 [X] 4 * (Figure, Materials and Methods) * [A] 1, 5-6
INTERNATIONAL-SEARCH-REPORT- OIKE T. et al., "Chromatin-regulating proteins as targets for cancer therapy.", J. Radiat. Res., (20140211), vol. 55, no. 4, ISSN 0449-3060, pages 613 - 628, XP055221487 [A] 1, 4-6 * (Abstract) *
INTERNATIONAL-SEARCH-REPORT- OGIWARA H. et al., "CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes.", PLoS One, (20120000), vol. 7, no. 12, page e52810, XP055221486 [X] 4 * (Figure, Materials and Methods) * [A] 1, 5-6
OPPOSITION- Comuzzi Barbara , Constanze Nemes Stefan Schmidt Zerina Jasarevic Michele Lodde Armin Pycha Georg Bartsch Felix Offner Zoran Culig Alfred Hobisch, "The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer", J. Pathol., (20040000), vol. 204, pages 159 - 166, XP055737726
OPPOSITION- Dr. Alessia Lenoci Dr. Stefano Tomassi Dr. Mariarosaria Conte Dr. Rosaria Benedetti Dr. Veronica Rodriguez Dr. Simone Carradori Prof. Daniela Secci Dr. Sabrina Castellano Prof. Gianluca Sbardella Dr. Patrizia Filetici Prof. Ettore Novellino Prof. Lucia Altucci Dr. Dante Rotili Prof. Antonello Mai, "Quinoline‐Based p300 Histone Acetyltransferase Inhibitors with Pro‐apoptotic Activity in Human Leukemia U937 Cells", ChemMedChem., (20140000), vol. 9, pages 542 - 548, XP055737793
OPPOSITION- Goodman Richard H., Sarah Smolik, "CBP/p300 in cell growth, transformation, and development", Genes Dev., (20000000), vol. 14, pages 1553 - 1577, XP002219086
OPPOSITION- Kohmei Ida, Issay Kitabayashi, Tomohiko Taki, Masafumi Taniwaki, Keiko Noro, Masao Yamamoto, Misao Ohki, Yasuhide Hayashi, "Adenoviral E1A-Associated Protein p300 Is Involved in Acute Myeloid Leukemia With t(11; 22)(q23; q13)", Blood, (19970000), vol. 90, no. 12, pages 4699 - 4704, XP055737743
OPPOSITION- Masahiro Kishimoto; Takashi Kohno; Koji Okudela; Ayaka Otsuka; Hiroki Sasaki; Chikako Tanabe; Tokuki Sakiyama; Chie Hirama; Issay Kitabayashi; John D Minna; Seiichi Takenoshita; Jun Yokota, "Mutations and Deletions of the CBP Gene in Human Lung Cancer", Clin. Res. Cancer, (20050115), vol. 11, no. 2, pages 512 - 519, XP055221483
OPPOSITION- ZOLA, "Monoclonal Antibodies", Encyclopedia of Life Sciences (ELS), Chichester, (20100000), XP055737487
OPPOSITION- Michalis V Karamouzis , Panagiotis A Konstantinopoulos, Athanasios G Papavassiliou, "Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis", Cell Res., (20070000), vol. 17, pages 324 - 332, XP055737486
OPPOSITION- Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera, "Inactivating mutations of acetyltransferase genes in B-cell lymphoma", Nature, (20110310), vol. 471, no. 7337, pages 189 - 195, XP055361688
OPPOSITION- Katherine C. Helming, Xiaofeng Wang , Boris G Wilson , Francisca Vazquez , Jeffrey R Haswell , Haley E Manchester , Youngha Kim , Gregory V Kryukov , Mahmoud Ghandi , Andrew J Aguirre , Zainab Jagani , Zhong Wang , Levi A Garraway , William C Hahn , Charles W M Roberts, "ARID1B is a specific vulnerability in ARID1A-mutant cancers", Nat. Med., (20140000), vol. 20, pages 251 - 4, XP055737468
OPPOSITION- Michael Haberland, Rusty L Montgomery, Eric N Olson, "The many roles of histone deacetylases in development and physiology: implications for disease and therapy", Nat. Rev. Genet., (20090000), vol. 10, no. 1, pages 32 - 42, XP055737773
OPPOSITION- Ogiwara H; Ui A; Otsuka A; Satoh H; Yokomi I; Nakajima S; Yasui A; Yokota J; Kohno T, "Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors", Oncogene, (20110000), vol. 320, pages 2135 - 2146, XP055221484
OPPOSITION- S Gramling, C Rogers, G Liu, and D Reisman, "Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy", Oncogene, (20110000), vol. 30, pages 3289 - 3294, XP055737496
OPPOSITION- Dawid Walerych, Marco Napoli, Licio Collavin, Giannino Del Sal, "The rebel angel: mutant p53 as the driving oncogene in breast cancer", Carcinogenesis, (20120000), vol. 33, no. 11, pages 2007 - 2017, XP055737602
OPPOSITION- Lan Wang, Alexander Gural, Xiao-Jian Sun, Xinyang Zhao, Fabiana Perna, Gang Huang, Megan A. Hatlen, Ly Vu, Fan Liu, Haiming Xu, Takashi Asai, Hao Xu, Tony Deblasio, Silvia Menendez, Francesca Voza, Yanwen Jiang, Philip A. Cole, Jinsong Zhang, Ari Melnick, Robert G. Roeder, Stephen D. Nimer, "The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation", Science, (20110805), vol. 333, no. 6043, pages 765 - 769, XP055737771
OPPOSITION- Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; S-I Watanabe; Nakano T; Yokota J; Kohno T, "A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1", CANCER RESEARCH,, (20130000), vol. 73, pages 5508 - 5518, XP055227924
OPPOSITION- Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T, "Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression", Cancer Disc., (20160400), vol. 6, no. 4, pages 430 - 445, XP055405240
OPPOSITION- Tomohiko Taki, Masahiro Sako, Masahiro Tsuchida, and Yasuhide Hayashi, "The t(11;16)(q23;p13) Translocation in Myelodysplastic Syndrome Fuses the MLL Gene to the CBP Gene", Blood, (19970000), vol. 87, no. 11, pages 3945 - 3950, XP055737734
OPPOSITION- Leila Haery; Juli n G Lugo-Pic; Ryan A Henry; Andrew J Andrews; Thomas D Gilmore, "Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth", Molecular Cancer, (20140000), vol. 13, no. 1, pages 1 - 13, XP021176935
OPPOSITION- Bedford David C., Paul K. Brindle, "Is histone acetylation the most important physiological function for CBP and p300?", Aging, (20120000), vol. 4, no. 4, pages 247 - 255, XP055737792
OTHER- KISHIMOTO et al., "Mutations and Deletions of the CBP Gene in Human Lung Cancer", Clin. Cancer Res., (20050000), vol. 11, pages 512 - 519, XP055221483
OTHER- M. Erin Bowers, Et Al.,, "Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor /NIH Public Access Author Manuscript/", Chem Biol./ PMC, (20110528), pages 1 - 24, XP055397622
OTHER- MULLIGHAN et al., "CREBBP mutations in relapsed acute lymphoblastic leukaemia /NIH Public Access Author Manuscript/", Nature/ PMC, (20110910), pages 1 - 13, XP055397612
OTHER- PASQUALUCCI et al., "Inactivating mutations of acetyltransferase genes in B-cell lymphoma", Nature, (20110310), vol. 471, no. 7337, pages 189 - 195, XP055361688
OTHER- OGIWARA et al., "Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors", Oncogene, (20110000), vol. 30, no. 18, pages 2135 - 2146, XP055221484
OTHER- YUAN et al., "Function for p300 and not CBP in the apoptotic response to DNA damage", Oncogene, (19990000), vol. 18, pages 5714 - 5717, XP055397617
OTHER- IYER et al., "Narayanan Gopalakrishna Iyer, Ozdag Hilal, Caldas Carlos", Oncogene, (20040524), vol. 23, no. 24, pages 4225 - 31, XP055397603
OTHER- Leila Haery; Juli?n G Lugo-Pic?; Ryan A Henry; Andrew J Andrews; Thomas D Gilmore, "Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth", Molecular Cancer, (20140215), vol. 13, no. 29, pages 1 - 13, XP021176935
OTHER- OGIWARA et al., "CBP and p300 Histone Acetyltransferases Contribute to Homologous Recombination by Transcriptionally Activating the BRCA1 and RAD51 Genes", PloS One, (20121220), vol. 7, no. 12, page e52810, XP055221486
SEARCH- KISHIMOTO MASAHIRO ET AL, "Mutations and deletions of the CBP gene in human lung cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 JAN 2005, (20050115), vol. 11, no. 2 Pt 1, ISSN 1078-0432, pages 512 - 519, XP055221483 [X] 4 * the whole document *
SEARCH- ZHI-MIN YUAN ET AL, "Function for p300 and not CBP in the apoptotic response to DNA damage", ONCOGENE, (19990101), vol. 18, no. 41, doi:10.1038/sj.onc.1202930, pages 5714 - 5717, XP055397617 [I] 1-6 * the whole document *
SEARCH- LEILA HAERY ET AL, "Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, (20140215), vol. 13, no. 1, doi:10.1186/1476-4598-13-29, ISSN 1476-4598, page 29, XP021176935 [I] 1-6 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents